Christopher Shen
Managing Director @ C-Bridge Capital
San Francisco, United States
Christopher Shen is a Series C investor at C-Bridge Capital in San Francisco focused on Medical and Health Care. Christopher Shen serves as a Partner at Novo Holdings.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Christopher Shen invests in
Stages Christopher Shen invests in
Countries Christopher Shen invests in
Investment Focus
Industry
- Medical 2 (100%)
- Health Care 2 (100%)
- Medical Device 2 (100%)
- Wearables 1 (50%)
Stage
- Series C 1 (50%)
- Series E 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $120M / Series E / Mar 26, 2025 | |
Element Science
|
Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietarynext-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards.The company was founded in 2011 and is headquartered in San Francisco, California. | $145.6M / Series C / Mar 03, 2020 |
Co-Investors
About C-Bridge Capital
C-Bridge Capital Partners identifies and unlocks opportunities to drive growth and development across borders. They leverage their expertise in the United States, China and Israel to help their global clients form international strategic alliances that achieve maximum returns. Using their unparalleled network and extensive knowledge, Theyfacilitate cross-border investments and asset formation in the US, China and Israel. They remain involved to monitor and protect their clients’ investment interests.
C-Bridge Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Wei Fu
Founder & Chief Executive Officer
|
|||
Abbas Hussain
Senior Partner
|
|||
|
Christopher Shen
Managing Director
|
|||
Kang Lan
Managing Director
|
|||
|
Lu Yanxiang
Senior Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Christopher Shen invest in?
Christopher Shen invests primarily in Medical, Health Care and Medical Device startups, most often at Series C and Series E stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Christopher Shen last invest?
The most recent investment recorded for Christopher Shen closed in Mar 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
